Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavodelpar - OnKure Therapeutics

Next Previous
Drug Profile

Mavodelpar - OnKure Therapeutics

Alternative Names: HPP 593; REN-001 - OnKure Therapeutics

Latest Information Update: 13 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer High Point Pharmaceuticals; OnKure Therapeutics; vTv Therapeutics LLC
  • Class Acetic acids; Alkenes; Alkynes; Antihyperglycaemics; Antihyperlipidaemics; Fluorobenzenes; Morpholines; Phenyl ethers; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial myopathies; Inborn error metabolic disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Dyslipidaemias; Muscular atrophy
  • Suspended Inborn error metabolic disorders; Mitochondrial myopathies
  • Discontinued Diabetes mellitus; Glycogen storage disease type V; Muscle fatigue

Most Recent Events

  • 31 Dec 2025 Phase-I clinical trials in Dyslipidaemias in USA (unspecified route), before December 2025
  • 31 Dec 2025 Phase-I clinical trials in Muscular atrophy in USA (unspecified route), before December 2025
  • 04 Oct 2024 Reneo Pharmaceuticals has merged with OnKure Therapeutics to form OnKure Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top